Structural heterogeneity and intersubject variability of Aβ in familial and sporadic Alzheimer’s disease
- aInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158;
- bDepartment of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158;
- cDepartment of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, CA 94158;
- dDepartment of Biochemistry, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON MST 258, Canada;
- eDepartment of Pathology, University of Washington, Seattle, WA 98195;
- fGeriatric Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA 98108;
- gDepartment of Neurology, University of Washington, Seattle, WA 98195;
- hDepartment of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;
- iMolecular Geriatrics, Department of Public Health and Caring Sciences, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden;
- jDepartment of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, 141 57 Huddinge, Sweden;
- kDepartment of Geriatric Medicine, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden;
- lDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158
See allHide authors and affiliations
Contributed by William F. DeGrado, December 5, 2017 (sent for review August 30, 2017; reviewed by Wilfredo Colón and David M. Holtzman)

Significance
An expanding body of evidence argues that the Aβ and tau proteins share important characteristics of prion propagation to cause pathogenesis in Alzheimer’s disease (AD). Aβ and tau form a number of amyloids (β-sheet–rich structures) with distinct conformations (“strains”), some of which give rise to different diseases and associated pathologies. We develop new probes of amyloid structure and use these to identify conformational strains of Aβ in heritable and sporadic forms of AD patient samples. We demonstrate that distinct strains of Aβ can be discerned in different disease types, or in different brain compartments within a given patient. Our findings may potentially explain the spectrum of clinical and pathologic features observed in AD.
Abstract
Point mutations in the amyloid-β (Aβ) coding region produce a combination of mutant and WT Aβ isoforms that yield unique clinicopathologies in familial Alzheimer’s disease (fAD) and cerebral amyloid angiopathy (fCAA) patients. Here, we report a method to investigate the structural variability of amyloid deposits found in fAD, fCAA, and sporadic AD (sAD). Using this approach, we demonstrate that mutant Aβ determines WT Aβ conformation through prion template-directed misfolding. Using principal component analysis of multiple structure-sensitive fluorescent amyloid-binding dyes, we assessed the conformational variability of Aβ deposits in fAD, fCAA, and sAD patients. Comparing many deposits from a given patient with the overall population, we found that intrapatient variability is much lower than interpatient variability for both disease types. In a given brain, we observed one or two structurally distinct forms. When two forms coexist, they segregate between the parenchyma and cerebrovasculature, particularly in fAD patients. Compared with sAD samples, deposits from fAD patients show less intersubject variability, and little overlap exists between fAD and sAD deposits. Finally, we examined whether E22G (Arctic) or E22Q (Dutch) mutants direct the misfolding of WT Aβ, leading to fAD-like plaques in vivo. Intracerebrally injecting mutant Aβ40 fibrils into transgenic mice expressing only WT Aβ induced the deposition of plaques with many biochemical hallmarks of fAD. Thus, mutant Aβ40 prions induce a conformation of WT Aβ similar to that found in fAD deposits. These findings indicate that diverse AD phenotypes likely arise from one or more initial Aβ prion conformations, which kinetically dominate the spread of prions in the brain.
Footnotes
↵1C.C., T.L., and J.S. contributed equally to this work.
- ↵2To whom correspondence may be addressed. Email: william.degrado{at}ucsf.edu or stanley.prusiner{at}ucsf.edu.
Author contributions: C.C., T.L., J.S., W.F.D., and S.B.P. designed research; C.C., J.S., M.N., Y.W., A.M.M., C.D.C., and A.O. performed research; J.C.W. and K.G. contributed new reagents/analytic tools; C.D.K., T.D.B., S.G.v.D., L.L., M.I., and C.G. provided human brain samples; C.C., T.L., J.S., M.N., Y.W., W.F.D., and S.B.P. analyzed data; and C.C., T.L., J.S., W.F.D., and S.B.P. wrote the paper.
Reviewers: W.C., Rensselaer Polytechnic Institute; and D.M.H., Washington University School of Medicine.
Conflict of interest statement: The Institute for Neurodegenerative Diseases has a research collaboration with Daiichi Sankyo (Tokyo, Japan). S.B.P. is the chair of the Scientific Advisory Board of Alzheon, Inc., which has not contributed financial or any other support to these studies.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714966115/-/DCSupplemental.
- Copyright © 2018 the Author(s). Published by PNAS.
This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).
Citation Manager Formats
Article Classifications
- Biological Sciences
- Neuroscience